Steigerwald Gordon & Koch Inc. Increases Holdings in McKesson Co. (NYSE:MCK)

Steigerwald Gordon & Koch Inc. grew its holdings in McKesson Co. (NYSE:MCK) by 4.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 37,460 shares of the company’s stock after buying an additional 1,452 shares during the quarter. McKesson makes up about 2.4% of Steigerwald Gordon & Koch Inc.’s investment portfolio, making the stock its 17th largest holding. Steigerwald Gordon & Koch Inc.’s holdings in McKesson were worth $21,349,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. MidAtlantic Capital Management Inc. purchased a new stake in McKesson in the third quarter worth $29,000. Wolff Wiese Magana LLC raised its holdings in McKesson by 742.9% in the 3rd quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock worth $29,000 after purchasing an additional 52 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of McKesson in the 3rd quarter worth about $31,000. ORG Wealth Partners LLC bought a new stake in shares of McKesson during the 3rd quarter valued at about $40,000. Finally, Bruce G. Allen Investments LLC increased its position in shares of McKesson by 51.9% during the fourth quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company’s stock valued at $47,000 after buying an additional 28 shares during the period. 85.07% of the stock is currently owned by institutional investors.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the transaction, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. This trade represents a 40.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.11% of the company’s stock.

McKesson Stock Performance

Shares of NYSE MCK opened at $592.69 on Friday. The firm’s 50 day moving average price is $595.11 and its 200-day moving average price is $561.34. McKesson Co. has a 52-week low of $464.42 and a 52-week high of $637.51. The company has a market cap of $75.24 billion, a PE ratio of 30.69, a P/E/G ratio of 1.26 and a beta of 0.52.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business had revenue of $93.65 billion for the quarter, compared to analysts’ expectations of $89.33 billion. During the same period in the prior year, the firm posted $6.23 EPS. The firm’s quarterly revenue was up 21.3% on a year-over-year basis. On average, analysts forecast that McKesson Co. will post 32.73 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend was Monday, December 2nd. McKesson’s payout ratio is presently 14.71%.

Analysts Set New Price Targets

MCK has been the subject of several research analyst reports. StockNews.com upgraded shares of McKesson from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Morgan Stanley raised their target price on McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company upped their price target on McKesson from $535.00 to $641.00 and gave the stock an “equal weight” rating in a research note on Friday, December 13th. Deutsche Bank Aktiengesellschaft lowered their price objective on McKesson from $623.00 to $579.00 and set a “buy” rating for the company in a research report on Wednesday, September 25th. Finally, Citigroup reduced their target price on shares of McKesson from $713.00 to $677.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.